Hepion Pharmaceuticals, Inc.
Hepion Pharmaceuticals, Inc. (HEPA) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
hepa · stock forecast · 3 analysts (3M) · FMP · updated Jun 9, 2026
Analyst Rating & Consensus
Based on 3 Wall Street analysts in the past 3 months
Hold
3 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$70.00
Consensus
$70.00
+114654.1% upside
Low
$70.00
Median: $70 · Last Close: $0.06
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Short-Term Price Prediction
Short-term predictions are paused during the ±3-day earnings window to avoid unreliable signals.
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
NEUTRAL
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · HEPA · Jun 9, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2023-12-07 | Brookline Capital | Downgrade ↓ | Buy→Hold |
| 2022-02-28 | Cantor Fitzgerald | Maintains | Overweight→Overweight |
| 2019-11-22 | Brookline Capital | Maintains | Buy→Buy |
| 2019-03-20 | Maxim Group | Downgrade ↓ | Buy→Hold |
| 2018-07-10 | Maxim Group | Upgrade ↑ | Hold→Buy |
| 2016-05-06 | Maxim Group | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on Hepion Pharmaceuticals, Inc. (HEPA) stock. Of the recent 6 rating actions, 1 were upgrades and 2 were downgrades. 3 analysts currently cover HEPA.
Analyst Recommendation Trends
HEPA analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 0 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$20M
Revenue Next Year
$0M
↓ 100.0% YoY
EPS This Year
$-72800.00
EPS Next Year
$-571.50
↓ 99.2% YoY
EPS ForecastReported vs Estimated
Analysts forecast HEPA EPS of $-72800.00 for the current fiscal year, based on estimates from 1 analysts. The HEPA revenue forecast is $20M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The HEPA stock forecast is supported by two independent data sources: analyst consensus ratings from 3 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus HEPA price target is $70.00 (+114654.1% upside), with an analyst consensus of Hold.
Hepion Pharmaceuticals, Inc. trades on OTC under the ticker HEPA. The HEPA stock outlook for 2027 is broadly mixed, supported by a Hold consensus among 33% of covering analysts.
Frequently asked questions
HEPA forecast · 8 questionsAccording to 3 Wall Street analysts, the average 12-month HEPA price target is $70.00, with a high forecast of $70.00 and a low of $70.00. The median price target is shown in the chart above when available. This implies +114654.1% potential upside from the current price of $0.06.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.